1 – 3 of 3
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden
(
- Contribution to journal › Article
- 2018
-
Mark
Uptake of rheumatology biosimilars in the absence of forced switching
(
- Contribution to journal › Article
-
Mark
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
(
- Contribution to journal › Article